Skip to main content

Human Genome Sciences (NASDAQ:HGSI) Investor Files Lawsuit Against Directors Over Alleged Breaches Of Fiduciary Duties In Connection With The Proposed Takeover By GlaxoSmithKline

  • If you purchased shares of Human Genome Sciences (NASDAQ:HGSI) prior to July 13, 2012, and currently hold any of those ASDAQ:HGSI shares, you have certain options and you should contact the Shareholders Foundation, Inc.

  • To have your information reviewed for options and to receive notifications about this case, please send an email to mail@shareholdersfoundation.com, or call us at (858) 779-1554.

Site Members can sign up for company wide alerts

Lawsuit Overview

July 24, 2012 (Shareholders Foundation) -- An investor in shares of Human Genome Sciences (NASDAQ:HGSI) filed a lawsuit against directors of Human Genome Sciences in effort to block the proposed takeover of Human Genomes Sciences by GlaxoSmithKline at $14.25 per NASDAQ:HGSI share. The plaintiff alleges that defendants breached their fiduciary duties owed to NASDAQ:HGSI investors aris...



You must register (for free) or login to view the entire case.